Article Text

Download PDFPDF
Systematic review
Sublingual immunotherapy improves symptoms of allergical rhinoconjunctivitis and asthma
  1. Deborah A Gentile
  1. Division of Allergy, Asthma and Immunology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
  1. Correspondence to: Dr Deborah A Gentile, Division of Allergy, Asthma and Immunology, Allegheny General Hospital, 320 E North Avenue, Pittsburgh, PA 15212, USA; dgentile{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Allergical rhinoconjunctivitis (ARC) and asthma are among the most prevalent chronic disorders affecting the US population, and contribute significantly to morbidity, direct and indirect healthcare costs and quality-of-life issues. Specific immunotherapy remains as a mainstay of treatment for these diseases and has traditionally been administered subcutaneously over an extended treatment period to desensitise allergical patients and improve their symptoms. Over the last several years, European regulatory authorities have approved1 the use of sublingual immunotherapy to treat allergical diseases and nearly 45% of allergen-specific immunotherapy is currently administered via this route in those countries.2 The advantages of sublingual immunotherapy over subcutaneous immunotherapy include ease of administration, avoidance of injections and convenience of home administration. In the USA, there are currently no …

View Full Text


  • Competing interests None.